MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clon.2025.103900

Медицинская библиотека · Clinical oncology (Royal College of Radiologists (Great Britain)) · 2025

Real-World Experience of 18F-PSMA-1007 Positron Emission Tomography-Computed Tomography Scanning for Initial Staging of High-Risk Nonmetastatic Prostate Cancer: Scan Results and Treatment Decisions.

Staffurth J, Mukherjee S, Fielding P, Renninson E, Rees J I

СтатьяПеревод в очереди

Аннотация

AIMS: Recent literature has shown the higher accuracy of staging prostate-specific membrane antigen positron emission tomography (PSMA-PET) scans over conventional imaging for high-risk localised prostate cancer patients suitable for radical treatment. All-Wales guidelines recommended PSMA-PET scans prior to radical therapy in 2020.

MATERIALS AND

METHODS

We have studied the outcome of high-risk prostate cancer patients referred for a staging PSMA-PET CT scan in Cardiff to identify the proportion for nodal or distant metastases, the association between risk factors and PET positivity, how treatment varied by PET result, and the outcome of men undergoing surgery.

RESULTS

Two hundred men underwent staging PSMA PET scans, of whom 143 had no evidence or suspicion of nodal or distant metastases on conventional imaging. Of these 143 patients, 102 (71%), 25 (17.5%), and 16 (11.2%) had post-PET staging of TxN0M0 (PETN0M0), TxN1M0 (PETN1M0) and TxNxM1 (PETM1), respectively. The risk of harbouring microscopic nodal or distant metastases was 12%, 38%, and 72% for men with 1, 2, or 3 high-risk factors, respectively. The risk also increased as the extent of each risk factor increased. The nodal false negative rate for the 22 men with PETN0M0 disease undergoing prostatectomy was 9.1%, despite the median number of nodes identified being only 8. Considering the entire 200-patient cohort, treatment was strongly influenced by PET results: 56% of PETN0M0 men had radical treatment to the prostate and 37% to prostate + nodes, 87% of PETN1M0 men had prostate and pelvic nodal radiotherapy with long-course androgen deprivation therapy (ADT) ± androgen receptor pathway inhibitor (ARPI), whereas 95% of men with PETM1 disease had permanent ADT therapy ± radiotherapy ± ARPI.

CONCLUSIONS

Our results reflect international literature and strongly support the role of staging PSMA-PET scans prior to radical therapy in all high-risk prostate cancer patients. Extension to unfavourable intermediate-risk should be considered.

Для цитирования: Staffurth J, Mukherjee S, Fielding P, Renninson E, Rees J I. Real-World Experience of 18F-PSMA-1007 Positron Emission Tomography-Computed Tomography Scanning for Initial Staging of High-Risk Nonmetastatic Prostate Cancer: Scan Results and Treatment Decisions.. Clinical oncology (Royal College of Radiologists (Great Britain)). 2025. DOI: 10.1016/j.clon.2025.103900.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.